BioHemp to Launch its Own Cosmetic Line of CBD Infused Topicals

(NEW YORK) – BioHemp International, Inc. (OTC: BKIT), (“Company”), a Company focused on consolidating distributors in the CBD industry, announces plan to launch its own cosmetic line of CBD infused topicals.

The Company is pleased to announce it is moving forward with filing its application to relist back current, and is working diligently to provide all requested documentation, and is working tirelessly to retain its fully reporting status.

BioHemp CBD Cosmetic Line

The Company has retained a manufacturing firm who will provide us a complete turnkey solution from packaging to labeling in launching our own cosmetic line of CBD infused topicals under the BioHemp brand name.

The initial focus will be targeted for online sales as this would offer us the highest margins for the least amount of capital outlay, and will allow us to build a marketing and awareness campaign to help build up the BioHemp cosmetic brand line with consumers.

Once we have established our branding, and solid customer loyalty, we will expand our distribution to wholesale and retail markets to help expand our revenue sales. This will require us to bring on experienced sales and distribution personal who can leverage their know how, and connections with industry, to establish market share of Biohemp CBD cosmetics within this sector.

Some of Potential CBD Cosmetic Lines

Broad Spectrum Cream
Calming Relief Cream with MSM
Fast Absorbing Capsaicin Cream
Matcha Anti-Aging Cream
Exfoliating Facial Scrub
Exfoliating Sugar Facial Scrub
Moisturizing Lip Scrub
Menthol Salve
Body Butter
Massage Oil – Lavender, Menthol, or Sensitive Skin
Pain Stick Tube

The Company expects to announce pricing models for its initial products in coming updates.

Pending FDA Guidance

As a regulatory framework from the Food & Drug Administration (FDA) still remains in limbo we feel the best course of action is to focus on launching a cosmetic line, build brand awareness and customer loyalty through online ecommerce sales, and work internationally in regards to any and all CBD infused edibles for the immediate future.

Daniel Blum, CEO of BioHemp International, commented, “Our number one priority has been getting the company back compliant and trading current, and we are very pleased to announce we are making big progress on that front. But, while we work on that pressing issue, we also know it is important for us to begin developing commercial products, and start building the Biohemp brand with customers and consumers. It has been a rough road these past few months to say the least, but we want to thank our shareholders for their loyalty, and understanding, and want to wish everyone a happy and healthful Thanksgiving holiday season.”

A more detailed and official announcement on these developments are expected shortly.

Register for Future Updates

Investors can also join our investor mailing list to receive updates on news, and special announcements, and add their mailing list for future investor packets and brochures as we begin our marketing and advertisement campaigns. https://www.biohempinternational.com/investors/

Follow us on Twitter: https://twitter.com/BiohempB

About BioHemp International

Located in New York City, BioHemp International is an early stage venture firm focused on establishing a portfolio of product brands, and distribution channels, for the growing cannabidiol (CBD) market. The Company’s management team holds years of experience in private equity, startup development, and financial consulting, which they plan to utilize in developing out future growth through strategic rollups and acquisitions. www.biohempinternational.com

FDA Disclaimer

The statements made regarding products on this website have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from healthcare practitioners. Please consult your healthcare professional about potential interactions or other possible complications before using any product. The Federal Food, Drug, and Cosmetic Act requires this notice.

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995) cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. BioHemp International, Inc undertakes no obligation to revise these statements following the date of this news release. Additional details of the Company’s business can be found in its public disclosures as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

Contact:

BioHemp International
244 5th Avenue, Suite A-154
New York, NY 10001
Phone: 646-453-4912
Email: d_b@biohempinternational.com

About author

Share